What Xenetic Biosciences Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 1 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 100,000 |
| Disposed | 0 | 0 |
| Net activity | +0 | +100,000 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Parslow James F | Interim CEO and CFO | Apr 21 | Grant / award · A | +100,000 | — | — | 100,000 |
| Genkin Dmitry | Director | Jul 19 | Grant / award · A | +93,390 | — | — | 93,603 |
| Genkin Dmitry | Director | Mar 14 | Other Transaction · J | −29,452 | — | — | 2,549 |
| Eisenberg Jeffrey F | CEO | Oct 26 | Grant / award · A | +50,000 | — | — | 50,000 |
Loading...
